Close Menu

restructuring

The company said that it is extending the maturity of certain obligations under the terms of the acquisition deal until March 2019.

After a 54 percent quarter over quarter rise in sales of the test, Rosetta's CEO said that the realigned strategy will take the firm to profit more quickly. 

As part of the deal with an institutional investor, Interpace's royalty and milestone obligations will also be terminated. 

The company will pay nearly $2.1 million to the liquidating trust for the now-bankrupt HDL in order to resolve outstanding debt from a former joint lab venture.

As part of a restructuring and cost reduction plan the firm also reduced the principle of its 2016 convertible note by about half.

The moves are part of an effort to consolidate and reduce costs related to administrative, finance, and operational support functions.

The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.

The company reported drops in revenues for both its human health and environmental health units, blaming challenging market conditions for the decreases.

The company beat analysts' consensus estimates on both the top and bottom lines as its molecular diagnostics sales rose 9 percent at constant exchange rates.

The company said the diagnostics unit will be focused on reproductive health, diagnostics for emerging markets, and applied genomics.

Pages

In a letter, about two dozen researchers criticize the World Health Organization investigation into the origins of SARS-CoV-2 and call for a new inquiry, the Wall Street Journal reports.

National Geographic reports that nine great apes at the San Diego Zoo have been vaccinated against SARS-CoV-2.

Janet Woodcock, the acting commissioner of the US Food and Drug Administration, speaks with NPR about SARS-CoV-2 testing and vaccines in the US.

In Science this week: genetic study of kidney fibrosis implicates the SOX9-NAV3-YAP1 axis.